Global Regulatory Intelligence
Designing a Single Evidence Strategy for Multiple Regulatory Jurisdictions
Executive Summary
A medical device company was preparing to expand beyond the United States and pursue commercialization in Europe, Canada, Australia, and other international markets. While the organization had already established a preliminary FDA regulatory strategy, leadership was concerned that decisions being made today could create unnecessary complexity, duplicate evidence generation, and increase costs as additional jurisdictions were pursued.
Before committing to its development plan, the company used Agent Astro to evaluate regulatory requirements across multiple markets and identify opportunities to harmonize evidence generation, standards compliance, testing strategies, and submission planning.
The analysis revealed that while many requirements overlapped, several critical differences could significantly affect future timelines, study design, documentation, and market entry strategies. By identifying these issues early, the company was able to develop a more unified global regulatory approach and reduce the risk of expensive rework later in the product lifecycle.
Key Questions Addressed
Can one development program support multiple jurisdictions?
Which studies and testing activities can be reused globally?
Where do regulatory requirements diverge?
Which standards should guide product development?
What decisions today could create future international barriers?
How can evidence generation be optimized across markets?
The Situation
The company planned to launch its device in the United States first, followed by expansion into Europe and other international markets. Historically, the organization approached each jurisdiction separately.
This often resulted in:
- •Duplicated testing
- •Repeated documentation efforts
- •Inconsistent evidence packages
- •Delayed market entry
- •Higher development costs
The Challenge
Although many regulatory frameworks share common principles, significant differences remain.
A development strategy optimized solely for FDA requirements may not fully support:
- •EU MDR expectations
- •Health Canada requirements
- •Australian TGA requirements
- •Japanese PMDA expectations
How Agent Astro Approached the Problem
Agent Astro evaluated the device and development program through a global regulatory lens
Cross-Jurisdiction Regulatory Analysis
The platform reviewed requirements across multiple regulatory frameworks, including:
- FDA
- EU MDR
- Health Canada
- TGA
- Selected international markets
The analysis identified both areas of alignment and areas of divergence.
Standards Harmonization
Agent Astro mapped applicable standards across jurisdictions, including:
- ISO 13485
- ISO 14971
- IEC 62304
- ISO 10993
- IEC 62366
- Other applicable standards
The goal was to identify opportunities where a single compliance effort could support multiple regulatory objectives.
Evidence Reuse Assessment
The platform evaluated proposed testing and validation activities to determine:
- Which studies could support multiple jurisdictions
- Where additional evidence would likely be required
- Which regulatory expectations created the greatest risk of duplication
Strategic Market Sequencing
Agent Astro assessed how different market entry strategies could affect:
- Development timelines
- Evidence generation
- Regulatory burden
- Future submission efficiency
Alternative sequencing approaches were evaluated to support leadership decision-making.
Findings
Most Evidence Requirements Overlapped More Than Expected
The analysis identified substantial opportunities to design studies and testing activities that would satisfy multiple jurisdictions simultaneously.This created potential efficiencies across the development program.
Several Regulatory Differences Had Outsized Impact
While many requirements were aligned, a small number of jurisdiction-specific expectations had the potential to create significant downstream complexity if not addressed early.These became priorities during development planning.
Standards Selection Would Influence Future Regulatory Flexibility
The choice of standards and documentation structure had implications far beyond the initial Regulatory context.Adopting globally recognized frameworks early would simplify future expansion efforts.
Market Sequencing Influenced Regulatory Efficiency
Different commercialization sequences produced different evidence requirements and development burdens.The analysis identified several approaches that improved long-term efficiency while supporting near-term business objectives.
The Decision
Following the analysis, the company adopted a globally informed development strategy rather than a jurisdiction-specific approach.
The team:
- aligned testing plans across markets
- selected standards with broader international applicability
- adjusted evidence generation plans
- updated documentation structures
- incorporated future international expansion into current planning decisions
Outcome
The organization gained a clearer understanding of how today's development decisions would affect tomorrow's international opportunities. Rather than treating each jurisdiction as an independent project, leadership was able to evaluate regulatory requirements as part of a connected global strategy. The result was a more efficient development program, reduced risk of duplicate work, and greater confidence that evidence generated today would continue creating value as new markets were pursued.
Capabilities Demonstrated
Conclusion
The most efficient global regulatory strategies are designed before the first submission is filed. By connecting regulatory requirements, standards, evidence expectations, and market-entry objectives across jurisdictions, Agent Astro helps organizations build development programs that support not just one approval, but a global commercialization strategy.
Other Insights & Case Studies
Regulatory Pathway Intelligence
Avoiding a Multi-Million Dollar Regulatory Misstep Before Development Begins
Q-Sub Planning & FDA Engagement Intelligence
Preparing for an FDA Meeting Before Critical Decisions Become Expensive